Premium
The cost of the inpatient management of febrile neutropenia in cancer patients – a micro‐costing study in the I rish healthcare setting
Author(s) -
O'Brien C.,
Fogarty E.,
Walsh C.,
Dempsey O.,
Barry M.,
Kennedy M.J.,
McCullagh L.
Publication year - 2015
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/ecc.12182
Subject(s) - medicine , activity based costing , context (archaeology) , febrile neutropenia , health care , emergency medicine , cohort , pediatrics , intensive care medicine , neutropenia , surgery , chemotherapy , paleontology , marketing , economics , business , biology , economic growth
The objective was to evaluate the resource use and cost of hospitalisation for febrile neutropenia ( FN ) from the health‐payer's perspective. This was a single centre study. Adults undergoing chemotherapy, who were admitted for FN , were identified prospectively. Patient medical records were reviewed retrospectively. Demographics and resource utilisation data were obtained from a cohort of 32 patients (69% female, mean age = 58.8 years). Twenty‐five per cent of patients had more than one FN episode. In total, 42 FN episodes were captured; 60% of episodes had occurred within the first two cycles of chemotherapy. The bootstrap estimation was used to determine mean hospital length of stay ( LOS ) with standard deviation (±SD) and mean costs ± SD. The mean LOS was 7.3 ± 0.5 days. The mean cost per FN episode was €8915 ± 718. The major cost driver was hospital bed‐stay (mean cost of €6851 ± 549). Other cost drivers included antibacterial treatment at €760 ± 156, laboratory investigations at €538 ± 47 and the requirement for blood bank products at €525 ± 189. To our knowledge, this is the first investigation of the cost of chemotherapy induced FN within the context of the I rish healthcare setting.